Memorable trades executed and commentaries for the prior week.
October 28. 2-24 to November 1, 2024
An initial investment of $10.000 produced $63,273.14 in net gains from the companies of the memorable trades. Naturally, the results as stated may not represent future transactions, but if history is the judge, our G-101-SPM AI algorithm is the TRUTH.
Thanks for giving us a look.
Our AI algorithm is an investment predictor that gathers data from 129 preset sources and presents the values as a SPM matrix number. The database tracks over 5215 individual stocks with each one carrying a "floating" SPM tag. The higher the value the greater the subjective probability of the collective data being accurate, and culminating with the issuance of an auxiliary SPM tag.
^Follow the daily abstracts for the best ideas and commentaries.
^DAC means “dollar average cost” and determines the true cost of the investment position during the cycle of the trade.
IDEA: Devote quality time to understand how to apply the data as a "positional investor."
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
MISSION STATEMENT: To prove that non-human intervention by an analytical chatbot is far superior than the other kind. The rise of generative AI (GenAI) models, like OpenAI’s GPT, has accelerated our transformation. These tools do more than process data, G-101 SPM AI generates meaningful content, automate workflows, and unlock insights in ways traditional AI could never achieve.
*G-101 SPM AI PORTFOLIO REPORT CARD:
For the month ending October 31, 2024, 94 symbols were posted, with twenty-nine [29] were liquidated at a gain and two [2] were liquidated at a loss. **
^^ Accuracy percentage rating for October 31, 2024 from the results of net position liquidation was 93.10 % versus 85.52% for the prior month.
^^ From March 9, 2023 to October 31, 2024, 2508 symbol were posted with an accuracy rating of 97.05 versus 85.02% (prior month) at liquidation and net of unrealized positions.
____
* Modification of portfolio’s calculations and summaries.
Since commencing postings, we elected to present “performance” based on net statistical values. Using a quantified method as to the algorithms’ accuracy offers a more concise indicator.
Effective September 27, 2024, the new formula:
+ symbol +prediction = percentage result at liquidation.
** Click SEARCH (magnifying glass) icon on our landing page to review all trades.
11.1.24
$ARDX $5.92 bid. DAC (dollar average cost includes prior sales of 38% of original position to reduce cost to zero, last sale at $7.94 [5.3.24]) EXIT $15.00. UPDATE: ^ Total Revenue: $98.2 million in Q3 2024, up from $56.4 million in Q3 2023. ^IBSRELA Net Product Sales: $40.6 million in Q3 2024, nearly double from Q3 2023, with 15% growth from Q2 2024. ^XPHOZAH Net Product Sales: $51.5 million in Q3 2024, Net Loss: Approximately $800,000 or less than $0.01 per share in Q3 2024. ^Cash Position: $190.4 million as of September 30, 2024, with a pro forma cash balance of over $240 million after drawing $50 million from amended debt agreement. Click SEARCH (magnifying glass) icon on our landing page to review the postings.
10.31.24
$CGNX $44.10 bid. SELL/TAKE PROFIT on limited SPM tag. DAC (dollar average cost) $40.60 (10.29.24). note: Disappointing guidance - see prior post.
10.29.24
$CGNX $40.60 ask. BUY/NEW LONG POSITION carries SPM 87.53 tag to $49.00 in midterm.
10.31.24
$CRMD $9.94 bid. DAC (dollar average cost) (2) $3.425 last $2.94 (11.15.23). EXIT $25.00 - Legacy Holding status (3-years).
BRIEF: Needham analyst Serge Belanger maintains Cormedix (CRMD) with a Buy and raises the price target from $10 to $18.
10.30.24
$EXEL $32.80 bid. SELL/TAKE PROFIT. DAC (dollar average cost) $28.73 (10.29.24).
10.29.24
$EXEL $28.73 ask. BUY/ADD NEW POSITION carries SPM 87.07 ta to $32.00.
10.30.24
$CRMD $12.96 bid. DAC( dollar average cos) (2) $3.425 last $2.94 (11.15.23). EXIT $12.00.
BRIEF: Reports Q3 (Sep) loss of $0.05 per share vs ($0.12) FactSet consensus; revenues $10.7 mln.
note: Following FDA feedback, the Company is in the final stages of amending the clinical study protocol for Total Parenteral Nutrition, or TPN, and anticipates FDA submission by mid-November to align with our plans to operationalize the study in the first half of 2025. In addition, CorMedix remains on track with a real-world evidence study, the pediatric hemodialysis study, and the expanded access program for DefenCath.
10.30.24
$SMMT $21.52 bid. DAC (dollar average cost includes 60% of position sold at a profit to reduced original cost of $7.35 on 6.4.24 to not cost). EXIT $32.00 as Legacy Holding.
UPDATE: Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024.
^ Ivonescimab Monotherapy Became First Drug to Achieve Clinically Meaningful Benefit over Pembrolizumab Monotherapy in a Phase III Randomized Clinical Trial in NSCLC, HARMONi-2, Reducing Risk of Disease Progression or Death by 49% in First-Line PD-L1 Positive Advanced NSCLC.
^ Enrollment Completed in Global Phase III HARMONi Trial in 2L+ EGFRm Advanced NSCLC; Received Fast Track Designation from FDA; Topline Data Expected in Mid-2025
^ Raised $235 Million in Private Financing from Insiders & Leading Biopharma Institutional Investors
10.29.24
$UCTT $34.13 bid. DAC (dollar average cost (6) $34.48 last BUY $32.95 on 10.29.24.
MAINTAIN EXIT AT $65.00 LH.
BRIEF: TD Cowen maintains BUY / price target 57.00.
10.29.24
$SMR $21.78 bid. SELL/TAKE PROFIT ON REMAINING 50% OF LONG POSITION.
* DAC (dollar average cost includes prior sale to reduce net cost to $14.10). Last BUY on REVISIT was at $18.05 (10.16.24).
PLAN TO REVISIT ON SPM TAG's REVISED NOTICE.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
10.29.24
$ABEO $6.39 bid. DAC (dollar average cost) $4.21 (5.30.24). EXIT $9.00).
UPDATE: Announces the Company resubmitted its Biologics License Application to the U.S. FDA for prademagene zamikeracel, its investigational autologous cell-based gene therapy, as a potential new treatment for patients with recessive dystrophic epidermolysis bullosa note: Abeona expects the FDA to set a new Prescription Drug User Fee Act target action date for pz-cel. The review period for a resubmitted BLA is either two or six months from the resubmission date depending on the FDA's classification of a resubmission as Class 1 or Class 2, respectively.
^^ The FDA's decision on acceptance of a BLA resubmission is typically made within 14 calendar days following the resubmission.
10.29.24
$EYPT $12.02 last. SELL/TAKE PROFITS on weaker SPM tag.
DAC (dollar average cost) (2) $8.39 last $8.14 (6.20.24).
PLAN TO REVISIT.
... from a follower
Thanks for the input.
$EYPT was originally purchased at $8.64 and again at $8.14 on 06.20.24 and sold today at $12.02 (correction) when the SPM tag registered a contraction.
Talking profits is the final conclusion of the AI algorithm. We just follow instructions.
The current success rate of the platform is over 87% - what would you want us to do?
Next question: Did you BUY $EYPT at $8.14 in June 2024?
That event established the perspective of the trade.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
10.28.24
$OCS $16.98 +1.18 bid. DAC (dollar average cost) $10.05 (11.10.23). EXIT $25.00 - Legacy Holding status.
BRIEF: Under stealth accumulation reduced net float to under 26.15 M, according to SPM tag data; probable T/O bid.
10.28.24
$CADL $5.60 bid. DAC (dollar average cost includes 20% sale at $10.88 (4.5.24), 20% sale at $13.69 (5.15.24) and 20% sale at 13.14 (5.24.24)).
Original BUY at $1.04 (12.19.23).
EXIT on 40% balance of long position is $25.00 with designation as Legacy Holding.
UPDATE: Today announced three presentations at the 16th Annual International Oncolytic Virotherapy Conference (IOVC), taking place October 27-30, 2024, in Rotterdam, the Netherlands.
note: The presentations will showcase Candel’s advancements in innovative viral immunotherapies, including new data from the ongoing phase 1b clinical trial of CAN-3110 in recurrent high-grade glioma (rHGG), a presentation on a new multimodal immunotherapy candidate from the enLIGHTEN™ Discovery Platform, and a Company overview, focused on Candel’s broad clinical and preclinical pipeline.
* Click SEARCH (magnifying glass) icon on our landing page to review the postings.
10.28.25
$IBRX $5.77 bid. DAC (dollar average cost) (6) $4.62 last (10.23.24). EXIT $12.00 long term. OVERRVIEW: Company up 10% today based on Phase 1 trial launch for CD19 t-haNK cell therapy in South Africa. The QUILT 106 study is a bold moveImmunityBio's first natural killer cell-based trial in the regionaiming to enroll up to 100 patients by early 2025. Targeting non-Hodgkin lymphoma, the trial will test the therapy both as a standalone and alongside rituximab, positioning the company to deliver cutting-edge cancer treatments to a market often overlooked in advanced research. note: Focusing on liquid tumors, the company aims to generate critical data by the second half of 2025 that could reshape how cancer is treated.
10.28.24
$EYPT $9.75 bid. DAC (2) 8.39 last $8.14 (6.20.24). EXIT $19.00.
UPDATE: Today announced positive interim 16-week data for the ongoing Phase 2 VERONA clinical trial evaluating DURAVYU, an investigational sustained delivery therapy delivering patent-protected vorolanib, a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E, for patients with diabetic macular edema (DME). DURAVYU 2.7mg demonstrated an early, sustained, and clinically meaningful improvement in best-corrected visual acuity (BCVA) and anatomical control versus the aflibercept control arm. A favorable safety and tolerability profile continued for both DURAVYU arms.
note: The 2.7mg dose is also being evaluated in the Phase 3 pivotal trials for wet AMD. The Company expects to report the full topline results in the first quarter of 2025, once all patients complete the trial.
10.28.24
$SMR $18.94 bid. * DAC (dollar average cost includes 50% sale of long position to reduce net cost to $6.32. EXIT $25.00.
OVERVIEW: $AMZN) and $GOOG in mid-October announced substantial investments in SMR projects as they look to balance their climate goals with the growing energy demands of the data centers powering their various AI software. $ORCL announced to build a data center powered by SMRs.
“A nuclear power renaissance is underway with nuclear increasingly viewed as a solution which solves both the increased need for baseload power and the need to decarbonize,” wrote Craig-Hallum analyst Eric Stine in a recent note to investors.
note: Goldman Sachs estimates that global data center power consumption will grow 160% by 2030, driven by demand from artificial intelligence. Meanwhile, separate data from the International Atomic Energy Agency shows nuclear power production in North America potentially doubling by 2050.
* Click SEARCH icon on our landing page to review the postings.
ARE YOU READY TO MAKE BIG MONEY IN THE STOCK MARKET?
Commentaires